• Lalitha K Shankar, Heiko Schöder, Elad Sharon, Jedd Wolchok, Michael V Knopp, Richard L Wahl, Benjamin M Ellingson, Nathan C Hall, Martin J Yaffe, Alexander J Towbin, Michael D Farwell, Daniel Pryma, Tina Young Poussaint, Chadwick L Wright, Lawrence Schwartz, Mukesh Harisinghani, Umar Mahmood, Anna M Wu, David Leung, de VriesElisabeth G EEGEDepartment of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands., Ying Tang, Gillian Beach, and Steven A Reeves.
• Clinical Trials Branch, National Cancer Institute, Rockville, MD, USA. Electronic address: lalitha.shankar@nih.gov.
• Lancet Oncol. 2023 Mar 1; 24 (3): e133e143e133-e143.

AbstractAs the immuno-oncology field continues the rapid growth witnessed over the past decade, optimising patient outcomes requires an evolution in the current response-assessment guidelines for phase 2 and 3 immunotherapy clinical trials and clinical care. Additionally, investigational tools-including image analysis of standard-of-care scans (such as CT, magnetic resonance, and PET) with analytics, such as radiomics, functional magnetic resonance agents, and novel molecular-imaging PET agents-offer promising advancements for assessment of immunotherapy. To document current challenges and opportunities and identify next steps in immunotherapy diagnostic imaging, the National Cancer Institute Clinical Imaging Steering Committee convened a meeting with diverse representation among imaging experts and oncologists to generate a comprehensive review of the state of the field.Copyright © 2023 Elsevier Ltd. All rights reserved.

8 keywords...

hide…